{"id":22770,"date":"2023-10-17T18:59:00","date_gmt":"2023-10-17T18:59:00","guid":{"rendered":"https:\/\/www.prnasia.com\/story\/archive\/4241033_AE41033_0"},"modified":"2023-10-17T18:59:00","modified_gmt":"2023-10-17T18:59:00","slug":"neurologist-anthony-lang-presents-groundbreaking-news-on-parkinsons-disease-at-world-congress-of-neurology-2023","status":"publish","type":"post","link":"https:\/\/transmediavictoria.net.au\/?p=22770","title":{"rendered":"Neurologist Anthony Lang Presents Groundbreaking News on Parkinson’s Disease at World Congress of Neurology 2023"},"content":{"rendered":"

MONTREAL<\/span>, Oct. 18, 2023<\/span> \/PRNewswire\/ — During a plenary lecture at the 26th World Congress of Neurology<\/a><\/u>, Dr. Anthony Lang<\/span>, professor of neurology and Jack Clark Chair for Parkinson’s Disease Research, University of Toronto<\/span>, revealed a groundbreaking new model for identifying and studying Parkinson’s disease. This new approach will help researchers investigate biological aspects of the disease that may be detectable many years before symptoms begin to show.<\/p>\n

The new model outlines three criteria for identifying Parkinson’s disease based on distinct, measurable biological factors. Lang explained that this new biological model will allow doctors and researchers to understand Parkinson’s in deeper and more complex ways than current clinical models, which are limited to observing symptoms in individual patients.<\/p>\n

“We believe this is a radically different way of looking at Parkinson’s disease,” said Lang. “We’ve reached a point where, in the era of novel biomarkers \u2026 our research needs to be driven by biological determinants of the disease rather than simply limited to a clinical description of the signs and symptoms.”<\/p>\n

Novel Parkinson’s Classification Model Offers New Criteria for Defining Disease
<\/b>Parkinson’s is typically diagnosed by doctors identifying symptoms in a clinical setting. In recent decades, researchers have uncovered biological causes for the disease \u2014 including genetic factors and the presence of the synuclein protein in the brain \u2014 but until recently, methods to test for these biomarkers in living patients have been largely unavailable. Lang hopes this major step toward a biological model will drive research to investigate these biomarkers and give scientists a more complex understanding of the disease. This in turn may drive development of new diagnosis and treatment methods.<\/p>\n

Lang and his colleagues call this new model “SynNeurGe” (pronounced “synergy”), based on the three key biological aspects used to identify the disease and their important interactions: <\/p>\n